Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -75% and 91.67%, respectively, for the quarter ended March 2025. Do…
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do…
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Degenerative Disc Disease - Pipeline Insight, 2024" clinical trials has…